Condition Directory

Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Cancer. Browse Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

50397

Shown on this page

Current sort

How Cancer studies are organized in the registry

“Cancer” is the broadest term in the registry, and most oncology records list a specific cancer type rather than the umbrella word. If you are researching a particular diagnosis, the dedicated pages for that cancer type usually give a cleaner result set. Tumor-agnostic and basket studies are the exception — they often appear under generic terms instead of a single organ site.

Terms that often appear in related listings

solid tumor advanced solid tumors metastatic basket trial

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1057–1068 of 50,397 matching trials for Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Myeloma
Interventions: Clarithromycin, Dexamethasone, Ixazomib Citrate, Pomalidomide; Drug
Lead sponsor: Joseph Tuscano; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: La Jolla, California • Orange, California • Sacramento, California

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Entrectinib, Durvalumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: Tigard, Oregon • Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Dara-RVd, Tec-RVd; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions: ADCT-701; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC), Ovarian Cancer, Endometrial Cancer, Cervical Cancer Metastatic, Non-small Cell Lung Cancer (NSCLC)
Interventions: CR-002; Drug
Lead sponsor: Crescent Biopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Austin, Texas • Dallas, Texas • Fairfax, Virginia

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Stage 4 NSCLC
Interventions: Pfizer-BioNTech mRNA COVID-19 vaccine; Biological
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Lovastatin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 2,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 480
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more

Conditions: Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Interventions: Zolbetuximab, mFOLFOX6, CAPOX; Drug
Lead sponsor: Midhun Malla; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Cancer, Cervical Cancer
Interventions: Lorigerlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sarcoma Metastatic
Interventions: ICG INFUSION 5MG/KG; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 12 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Phildelphia, Pennsylvania

About this Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Cancer clinical trials

How Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Universal Immunization to Fortify Immunotherapy Efficacy and Response

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric Patients

About this Cancer clinical trials directory page